Diagnostic efficacy across dense and non-dense breasts during digital breast tomosynthesis and ultrasound assessment for recalled women
Loading...
Files
Published Version
Date
2022
Authors
Hadadi, I.
Clarke, J.
Rae, W.
McEntee, Mark F.
Vincent, W.
Ekpo, E.
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Published Version
Abstract
Background: To compare the diagnostic efficacy of digital breast tomosynthesis (DBT) and ultrasound across breast densities in women recalled for assessment. Methods: A total of 482 women recalled for assessment from January 2017 to December 2019 were selected for the study. Women met the inclusion criteria if they had undergone DBT, ultrasound and had confirmed biopsy results. We calculated sensitivity, specificity, PPV, and AUC for DBT and ultrasound. Results: In dense breasts, DBT showed significantly higher sensitivity than ultrasound (98.2% vs. 80%; p < 0.001), but lower specificity (15.4% vs. 55%; p < 0.001), PPV (61.3% vs. 71%; p = 0.04) and AUC (0.568 vs. 0.671; p = 0.001). In non-dense breasts, DBT showed significantly higher sensitivity than ultrasound (99.2% vs. 84%; p < 0.001), but no differences in specificity (22% vs. 33%; p = 0.14), PPV (69.2% vs. 68.8%; p = 0.93) or AUC (0.606 vs. 0.583; p = 0.57). Around 73% (74% dense and 71% non-dense) and 77% (81% dense and 72% non-dense) of lesions assigned a RANZCR 3 by DBT and ultrasound, respectively, were benign. Conclusion: DBT has higher sensitivity, but lower specificity and PPV than ultrasound in women with dense breasts recalled for assessment. Most lesions rated RANZCR 3 on DBT and ultrasound are benign and may benefit from short interval follow-up rather than biopsy. � 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Description
Keywords
Breast cancer , Breast density , DBT , Equivocal (RANZCR 3) , Ultrasound
Citation
Hadadi, I., Clarke, J., Rae, W., McEntee, M., Vincent, W. and Ekpo, E. (2022) 'Diagnostic efficacy across dense and non-dense breasts during digital breast tomosynthesis and ultrasound assessment for recalled women', Diagnostics, 12(6), 1477 (13pp) doi: 10.3390/diagnostics12061477